No Data
Qingdao Vland Biotech INC. (603739.SH): The export revenue to the USA market accounts for a very low proportion.
On April 15, Gelonghui reported that Qingdao Vland Biotech INC. (603739.SH) stated on the investor interaction platform that the company's products primarily export to countries and regions including the Philippines, Vietnam, Brazil, and Bulgaria. As of now, the company's business is mainly focused on the domestic market, with domestic business revenue accounting for about 92%, and the export revenue to the USA market being very low. Adjustments to the USA tariff policy will not have a significant impact on the company's operation.
Is There An Opportunity With Qingdao Vland Biotech INC.'s (SHSE:603739) 30% Undervaluation?
Qingdao Vland Biotech INC. (603739.SH): There are no products or research and development investments related to microplastics.
On April 3, Gelonghui reported that Qingdao Vland Biotech INC. (603739.SH) stated on the investor interaction platform that, as of now, the company has no products or R&D investments related to microplastics. For more product information, please refer to the periodic reports disclosed on the Shanghai Securities Exchange website.
Funds are being frantically invested, and pharmaceutical stocks are back in the spotlight! Bullish policies and fundamentals have arrived.
Performance is steadily increasing.
Qingdao Vland Biotech INC.'s (SHSE:603739) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Qingdao Vland Biotech INC. (603739.SH): plans to reduce the capital of its subsidiary Vland Pet by 60 million yuan.
On December 27, GELONGHUI reported that Qingdao Vland Biotech INC. (603739.SH) announced plans to reduce the capital of its wholly-owned subsidiary Vland Pet to 60 million yuan. After the completion of this capital reduction, Vland Pet's registered capital will decrease from 70 million yuan to 10 million yuan.
